Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab and Anlotinib with Radiotherapy for Anaplastic Thyroid Cancer
NCT05659186Phase 2Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Dec 2022
- Primary completion
- Dec 2024
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab, anlotinib in anaplastic thyroid cancer (ATC), sponsored by West China Hospital of Sichuan University. Started Dec 2022; status: recruiting.
02
Drugs
tislelizumabanlotinib
03
Conditions
anaplastic thyroid cancer (ATC)
Beyond the preview
Go deeper on NCT05659186.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05659186.